TY - JOUR AU - Rocha, Michelle Silva AU - Aquino, Lorenna Lemos de AU - Rodrigues, Ágda Tamires da Silva AU - Oliveira, Clarice Paiva de AU - Lazo, Lívia Mendes Montoya AU - Salviano, Juliana Leite AU - Valadão, Letícia Vieira AU - Batista, Marihana Miranda AU - Lopes, Vinícius Bezerra AU - Ribas Filho, Durval PY - 2021/11/04 Y2 - 2024/03/29 TI - COVID-19 and Psoriasis: A Concise Systematic Review JF - MedNEXT Journal of Medical and Health Sciences JA - MedNEXT VL - 2 IS - 4 SE - Articles DO - 10.54448/mdnt2143 UR - https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/60 SP - AB - <p><strong>Introduction:</strong><span style="font-weight: 400;"> The effects on human health caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) lead to hyperinflammation processes, which can lead to meta-inflammation. This process can aggravate skin diseases, especially psoriasis. This is a chronic inflammatory skin disease associated with significant morbidity. This problem affects about 2-3% of people worldwide. </span><strong>Objective:</strong><span style="font-weight: 400;"> to demonstrate, through a concise systematic review, the main considerations about the relationship between COVID-19 and psoriasis, showing the possible mechanisms for the worsening of this dermatological disease. </span><strong>Methods:</strong><span style="font-weight: 400;"> The research was carried out from June 2021 to July 2021 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar, following the Systematic Review-PRISMA rules. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. </span><strong>Results:</strong><span style="font-weight: 400;"> Psoriasis is a common chronic inflammatory skin disease and is autoimmune. Patients with COVID-19 may have features of hyper inflammation and even meta-inflammation. The triggering or exacerbating factor of psoriasis may be medications and, in addition, patients with COVID-19 may have psoriasis exacerbation. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. It is envisioned that the use of azithromycin in cases of COVID 19 with pre-existing psoriasis can alleviate psoriatic lesions. </span><strong>Conclusion:</strong><span style="font-weight: 400;"> The COVID 19 pandemic had a direct impact on dermatological diseases, especially psoriasis. Difficulty in accessing health care services and the stress load caused exacerbations in psoriasis cases. Studies recommend avoiding classic immunosuppressive agents such as methotrexate, cyclosporine, and TNF alpha inhibitors. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease.</span></p> ER -